

Task Force on Repurposing of Drugs (TFORD) for COVID-19

Patent status in India: by GNANLEX

Sepsivac**A: Active Patents**

| S.no. | Title | Assignee | Patent details | Type of patent | Remarks |
|-------|--|----------------------------|--|---|---|
| 1. | A process for the preparation of a pharmaceutical composition of killed cells with substantially retained immunogenicity | Cadila Pharmaceuticals Ltd | Grant No: IN297641 (464/MUM/2010) Filing date: 19/02/2010 Publication date: 14/06/2018 Form 27: not worked in India | Lyophilized composition of killed cancer cells. | Patent Barrier. However, can be worked around |

B: Pending Patents/patent applications:

| S.no. | Title | Assignee | Patent details | Type of patent | Remarks |
|-------|--|----------------------------|---|---|--|
| 1. | Mitogen Activated Protein Kinase Modulator | Cadila Pharmaceuticals Ltd | Application no. 1235/MUM/2007 Filing date: 28/06/2007 Publication date: 19/06/2009 FER issued: 26/02/2014 | <i>Mycobacterium w</i> (Mw) and/or constituents thereof as modulators of Mitogen activated protein kinases in mammal and/or mammalian cells. | No Patent Barrier, even if granted. |
| 2. | Cancer Antigen | Cadila Pharmaceuticals Ltd | Application no. 1929/MUM/2011 Filing date: 05/07/2011 Publication date: 13/12/2013 Reply to the FER issued on 11/02/2019 submitted by the Applicant. | Cancer antigen specific to cancer when treated with an agent from <i>Mycobacterium w</i> , cisplatin, paclitaxel, gemcitabine and combination thereof | No Patent Barrier, even if granted. |
| 3. | Therapeutic Cancer Vaccine | Cadila Pharmaceuticals Ltd | Application no. 555/MUM/2011 Filing date: 28/02/2011 Publication date: 31/08/2012 | Cancer vaccine composition | Patent Barrier, if granted for the vaccine |

Commissioned by



Task Force on Repurposing of Drugs (TFORD) for COVID-19

Patent status in India: by GNANLEX

C: Expired/Lapsed applications

| S.no. | Title | Assignee | Patent | Type of patent | Remarks |
|-------|--|----------------------------|--|--|-------------------|
| 1. | Immnomodulator For The Management of Human Immunodeficiency Virus (HIV) Disease/Infection | Cadila Pharmaceuticals Ltd | Application no. 50/MUM/ 2001 Filing date: 17.01.2001 Publication date 08/06/2007 | An immunomodulator for the management of human immunodeficiency virus(HIV) disease | No Patent Barrier |
| 2. | The process of manufacturing Immunomodulators to treat HIV disease infection | Cadila Pharmaceuticals Ltd | Application no. 47/MUM/2001 Filing date: 17/01/2001 Publication date: 12/08/2005 | process of manufacturing immunomodulators to treat HIV disease using cells of <i>Mycobacterium w</i> | No Patent Barrier |
| 3. | The Method Of Treating Human Immunodeficiency Virus (HIV) Disease/Infection | Cadila Pharmaceuticals Ltd | Application no. 49/MUM/2001 | Formulation containing <i>Mycobacterium w</i> for prophylaxis or therapy of AIDS | No Patent Barrier |
| 4. | The Method of Treating Cancer | Cadila Pharmaceuticals Ltd | Application no. 1167/MUM/ 2001 Filing date: 10/12/2001 | Formulation containing <i>Mycobacterium w</i> for treatment of cancer. | No Patent Barrier |
| 5. | The Process of Manufacturing a Pharmaceutical Composition Useful for Management of Cancer | Cadila Pharmaceuticals Ltd | Application no. 1166/MUM/2001 Filing date: 10/12/2001 | NA | No Patent Barrier |
| 6. | Method Of Providing Prophylaxis For Tuberculosis In HIV Positive Individuals | Cadila Pharmaceuticals Ltd | Application no: 81/MUM/2002 Filing date: 20/01/2002 | Formulation using <i>Mycobacterium w</i> for against tuberculosis in HIV positive individuals. | No Patent Barrier |
| 7. | Process For Preparing A Pharmaceutical Composition For Immunity Against Tuberculosis In HIV Positive Individuals | Cadila Pharmaceuticals Ltd | Application no: 80/MUM/2002 Filing date: 29/01/2002 | NA | No Patent Barrier |
| 8. | The process of manufacturing a pharmaceutical composition useful for management of tuberculosis | Cadila Pharmaceuticals Ltd | Application no: 236/MUM/2002 Filing date: 08/03/2002 | Pharmaceutical composition <i>Mycobacterium w</i> and carrier in a single formulation. | No Patent Barrier |

Commissioned by



Task Force on Repurposing of Drugs (TFORD) for COVID-19

Patent status in India: by GNANLEX

| | | | | | |
|-----|--|----------------------------|--|--|-------------------|
| 9. | The Method Of Treating Tuberculosis | Cadila Pharmaceuticals Ltd | Application no: 235/MUM/2002 | treating tuberculosis using a formulation containing <i>Mycobacterium w.</i> | No Patent Barrier |
| 10. | Use of Mycobacterium w in treatment of Bronchial Asthama | Cadila Pharmaceuticals Ltd | Application no: 246/MUM/2002 Filing date: 13/03/2002 | Treating Bronchial Asthama with <i>Mycobacterium w.</i> | No Patent Barrier |
| 11 | Process for manufacturing pharmaceutical composition comprises of Mycobacterium w in the treatment of Bronchial Asthama Attack | Cadila Pharmaceuticals Ltd | Application no: 247/MUM/ 2002 Filing date: 13/03/2002 | Pharmaceutical composition for the management of asthma (obstructive lung disease) containing <i>Mycobacterium w.</i> | No Patent Barrier |
| 12 | Poly-TLR Antagonist | Cadila Pharmaceuticals Ltd | Application no: 1931/MUM/2006 Filing date: 23/11/2006 | Pharmaceutical composition containing <i>Mycobacterium w.</i> for reducing induced Toll like receptor (TLR) activity. | No Patent Barrier |
| 13 | P38 Inhibitor | Cadila Pharmaceuticals Ltd | Application no: 509/MUM/2007 Filing date: 20/03/2007 | Use of <i>Mycobacterium w</i> (Mw) for inhibition of P38 protein kinase. | No Patent Barrier |
| 14 | Pharmaceutical composition for Non-Small Lung Cancer | Cadila Pharmaceuticals Ltd | Application no: 92/MUM/2011 Filing date: 11/01/2011 | use of <i>Mycobacterium w</i> in the treatment of desmocollin-3 expressing cancers | No Patent Barrier |
| 15 | Vaccine Adjuvants | Cadila Pharmaceuticals Ltd | Application no: 505/MUM/2005 Filing date: 25/04/2005 | <i>Mycobacterium w</i> and/or its constituent(s) as adjuvant and antigen (s) in a eliciting enhanced antigen associated immune response. | No Patent Barrier |

Disclaimer:

Search results are up to 21st May 2020

GNANLex's Opinion / Report as hereinabove is to the best of our knowledge, true and accurate as of the date compiled based on available information. However, no guarantee is made as to its accuracy, reliability or completeness. The final user is expected to assume sole liability for any patent infringement that occurs by following our recommendations or using the information given. Before

Commissioned by



Task Force on Repurposing of Drugs (TFORD) for COVID-19



Patent status in India: by GNANLEX

using, user should determine the suitability of the information for his intended use. The risk and liability, if any, in connection therewith, is solely that of the user.

Commissioned by

